歌礼制药有限公司（01672）于2025年12月17日发布翌日披露报表。公告显示，公司当日于香港联交所回购20万股普通股，最高回购价每股13.17港元，最低回购价每股12.55港元，合计付出约260.115万港元。该回购股份占公司现有已发行股本约0.0202%。
公司公告指出，回购股份暂拟注销但截至期终结存日期尚未注销，公司已发行股份总数仍维持991,874,320股，库藏股数为7,084,210股。根据此前于2025年5月22日通过的购回授权，公司可回购总数为96,284,628股。截至本次回购后，累计在交易所回购4,986,000股，占授权通过当日已发行股份总数的约0.5174%。
根据公告，公司确认上述回购行为符合香港联合交易所有限公司证券上市规则及相关法规。公告由公司秘书钟明辉签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.